|
|
 | | | |
- close
- close
- close
- close
| |||||||||
Synergetics USA 8-K 2012 Documents found in this filing:Exhibit 99.1
 1
March 2012
NEUROSURGERY
QUALITY. PERFORMANCE.
INNOVATION. OPHTHALMOLOGY
Investor Presentation
 2
Certain statements made in this presentation are forward-looking within
the meaning of the Private Securities Litigation Reform Act of 1995. Among other, statements concerning management’s expectations of future financial results, potential business, acquisitions, government agency approvals, additional indications and therapeutic applications for medical devices, as well as their outcomes, clinical efficacy and potential markets are forward looking. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted results. For a discussion of such risks and uncertainties, please refer to the information set forth under “Risk Factors” included in Synergetics USA, Inc.’s Annual Report on Form 10-K for the year ended July 31, 2011 and information contained in subsequent filings with the Securities and Exchange Commission. These forward looking statements are made based upon our current expectations and we undertake no duty to update information provided in this presentation. Safe Harbor Statement
2
 3
Overview
• Synergetics is a medical device company focused
in the ophthalmology and neurosurgery market • Synergetics USA, Inc. was formed through a
reverse merger of Synergetics, Inc. and Valley Forge Scientific in 2005 • Synergetics was founded in 1991 and Valley
Forge was founded in 1980 and became a publicly-held company in November 1989 • Synergetics USA, Inc. (NASDAQ: SURG)
• Corporate Headquarters: O’Fallon, MO
• Manufacturing Facilities: O’Fallon, MO and King
of Prussia, PA • Shares Outstanding: 25.18mm
• 52 Week Range: $4.61- $7.55
• Market Cap.: $161.13mm
• June 2011 added to Russell 2000 & 3000 Indexes
3
 4
Financial Comparison
4
 5
Financial Comparison
5
 6
Overview
• Major Events:
• Alcon Settlement
• Neurosurgery Transition
• Project Restore
• Lean Manufacturing Implementation
6
 7
Overall Strategy
• Drive Accelerating Growth in our Ophthalmology Business
• Manage our Neurosurgery and OEM Business for Stable
Growth and Strong Cash Flows • Deliver Improved Profitability through our Lean Initiatives
• Demonstrate Solid Financial Performance
7
 8
Markets
8
 9
2011 Anterior (Cataract) and
Posterior (Retinal) Markets Compared
9
 10
10
 11
Potential Game Changers
• Anti-VEGF Therapies (i.e. Lucentis)
• Long Term Drug Delivery Implants
• Artificial Vision
• Microplasmin Vitreous Disinsertion (Ocriplasmin)
• Site of Service Migration, e.g. ASC, Office
11
 12
Product Review
12
 13
Ophthalmology Products
Quantel Laser
Endoilluminator - Awh
Chandelier Photon II
13
 14
VersaPACK™
VersaVIT™
UVE
(Ultimate Vit Enhancer)
14
 15
Neurosurgery Products
(Marketing Partners/OEM ) The Disposable Spetzler-Malis
“Yellow” bipolar forceps offer surgeons brand-new, high-polished tips for guaranteed non-stick performance. Disposable
Bipolar Forceps
Our next generation Malis®
Bipolar Generator. Dual- waveform technology provides delicate and efficient cutting and coagulation control at even lower power settings, further reducing thermal spread and collateral tissue damage. The Advantage™
Stryker
Codman
The OMNI
The OMNI is the most innovative
and user-friendly ultrasonic aspirator available. In addition to the soft tissue removal capabilities common, it effectively addresses dense, fibrotic lesions, and pioneers the fine dissection of bone traditionally performed with rotating drills. 15
 16
Traditional OEM Products
Codman Synergy
Stryker Lesion
Generator 16
 17
Ophthalmology Product
Video 17
 18
Neuro Product Video
18
 19
Financials
19
 20
Financial Highlights - FY
2011 • Sales were up 21% for the fourth quarter ended July 31, 2011
with disposables sales up 23.0% and capital sales down 2.3%. • Sales were up 7.2% for the fiscal year ended July 31, 2011.
• Net income and earnings per share doubles.
• Total interest bearing debt decreased $3.0 million from FYE 2010
to approximately $1.1 million bringing our leverage down to 2.0%. • Post Alcon transaction (including payment of taxes), Company
has $18.4 million of cash on its balance sheet and has significantly reduced its debt. 20
 21
Financial Highlights - 2Q
2012 • Sales up 13.6% year-over-year to $15.1 million
• EBITDA up 42.4% year-over-year to $3.1 million
• Income from Continuing Operations up 41.9% year-over-
year to $1.9 million • Earnings per Share from Continuing Operations Up 40% to
$0.07 21
 22
Investment Rationale
• Improved stability of the platform
• Reinvigorating sales growth
• Unique, technically proficient worldwide distribution
capability • Opportunity to create “Fast Follower” that will be
viewed as an attractive entry vehicle to ophthalmology 22
 23
Management Team
• David M. Hable - President, CEO
Over 30 years of progressive responsibility in sales, marketing, new business development and
general management in the medical device industry. • Pamela Boone - Executive Vice President, CFO
Previously served as CFO, VP and Corporate Controller for Maverick Tube Corporation. 25 years
of financial expertise. • Kurt Gampp - Executive Vice President, COO
Co-founded Synergetics, Inc. Over 30 years of microsurgical instrument making experience.
• Jerry Malis, M.D. - Executive Vice President, CSO
Served as President, CEO and Chairman of Valley Forge. Over 40 years of industry experience.
Published over 50 articles in the biological science, electronics and engineering fields. Issued ten U.S. patents. • Michael Fanning - Vice President, Domestic Sales
Over 20 years in sales and management roles, working in service, medical device and
manufacturing sectors. • Jason Stroisch - Vice President, International Sales & Marketing
Over 15 years in the medical device industry covering engineering, international sales and
marketing management roles. • Phillip M. Williford - Vice President, Operations
Over 20 years of progressive responsibility in engineering and lean operations management
within snack food, automotive component part, pharmaceutical and medical device industries. • Joan Kraus - Vice President, Regulatory Affairs / Quality Assurance
Over 20 years in quality systems and process improvement roles working in healthcare,
manufacturing, distribution and service sectors. 23
 24
March 2012
NEUROSURGERY
QUALITY. PERFORMANCE.
INNOVATION. OPHTHALMOLOGY
Investor Presentation
3845 Corporate Centre Drive
O’Fallon, MO 63368
(636) 939-5100
www.synergeticsusa.com
|
| |||||||
